BE of parenterals [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-10-08 13:53 (2083 d 05:19 ago) – Posting: # 19416
Views: 3,541

Hi Varsha,

❝ As per guideline we need not to perform any Bioequivalence studies for Injectables.


It’s not that simple. See e.g., the EMA’s GL page 23.

❝ But Enoxaparin sodium being a biologically derived product, is there any need of performing the BA-BE studies.


That’s not the point. See the FDA’s guidance for conditions whether the in vivo PD (!) study can be waived.

❝ Does the guideline differs for a biologically derived product?


Differ to what? To get an idea, see the EMA’s guidelines on biosimilars.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,665 registered users;
39 visitors (0 registered, 39 guests [including 7 identified bots]).
Forum time: 19:13 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5